MARC HOROWITZ to Antineoplastic Combined Chemotherapy Protocols
This is a "connection" page, showing publications MARC HOROWITZ has written about Antineoplastic Combined Chemotherapy Protocols.
Connection Strength
0.234
-
Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol. 2005 Jan 20; 23(3):525-31.
Score: 0.051
-
Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors. Cancer. 1996 Aug 15; 78(4):901-11.
Score: 0.029
-
Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. J Clin Oncol. 1996 Mar; 14(3):901-10.
Score: 0.028
-
Brain tumors in the very young child. Postoperative chemotherapy in combined-modality treatment. Cancer. 1988 Feb 01; 61(3):428-34.
Score: 0.016
-
Therapy for childhood soft-tissue sarcomas other than rhabdomyosarcoma: a review of 62 cases treated at a single institution. J Clin Oncol. 1986 Apr; 4(4):559-64.
Score: 0.014
-
A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. J Neurooncol. 2006 Apr; 77(2):193-8.
Score: 0.014
-
Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol. 1998 Sep; 44(3):313-6.
Score: 0.008
-
A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. Cancer. 1995 Jun 01; 75(11):2762-7.
Score: 0.007
-
Postoperative chemotherapy and delayed radiation in infants and very young children with choroid plexus carcinomas. The Pediatric Oncology Group. Pediatr Neurosurg. 1995; 22(4):189-96.
Score: 0.006
-
Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol. 1993 Oct; 11(10):1911-8.
Score: 0.006
-
Response of pediatric low grade gliomas to chemotherapy. Pediatr Neurosurg. 1993 May-Jun; 19(3):113-8; discussion 119-20.
Score: 0.006
-
Neuraxis dissemination in pediatric brain tumors. Response to preirradiation chemotherapy. Cancer. 1992 Feb 15; 69(4):1061-6.
Score: 0.005
-
Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res. 1991 Sep; (270):8-14.
Score: 0.005
-
Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int J Radiat Oncol Biol Phys. 1991 Mar; 20(3):389-95.
Score: 0.005
-
Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas. Invest New Drugs. 1990 May; 8(2):181-2.
Score: 0.005
-
Phase II trial of ifosfamide in children with malignant solid tumors. Cancer Treat Rep. 1987 Feb; 71(2):131-5.
Score: 0.004
-
Hepatic undifferentiated (embryonal) sarcoma and rhabdomyosarcoma in children. Results of therapy. Cancer. 1987 Feb 01; 59(3):396-402.
Score: 0.004
-
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity. Cancer Chemother Pharmacol. 1987; 19(1):57-60.
Score: 0.004
-
Combination of dacarbazine and doxorubicin in the treatment of childhood rhabdomyosarcoma. Cancer Treat Rep. 1985 Sep; 69(9):999-1000.
Score: 0.003
-
The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neuro Oncol. 1999 04; 1(2):152-61.
Score: 0.002
-
Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol. 1996 Oct; 14(10):2818-25.
Score: 0.002
-
Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. J Neurooncol. 1996 May-Jun; 28(2-3):245-56.
Score: 0.002
-
Lack of efficacy of postoperative chemotherapy and delayed radiation in very young children with pineoblastoma. Pediatric Oncology Group. Med Pediatr Oncol. 1995 Jul; 25(1):38-44.
Score: 0.002
-
Sarcomas of the hand and foot: analysis of local control and functional result with combined modality therapy in extremity preservation. Int J Radiat Oncol Biol Phys. 1994 Jul 01; 29(4):735-45.
Score: 0.002
-
Desmoplastic infantile gangliogliomas: an approach to therapy. Neurosurgery. 1994 Apr; 34(4):583-9; discussion 589.
Score: 0.002
-
Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993 Jun 17; 328(24):1725-31.
Score: 0.001
-
Intensive combined modality therapy of small round cell and undifferentiated sarcomas in children and young adults: local control and patterns of failure. Radiother Oncol. 1989 Nov; 16(3):189-201.
Score: 0.001
-
The impact of delayed surgery on radiotherapy dose and local control of rhabdomyosarcoma. Arch Surg. 1987 Dec; 122(12):1451-4.
Score: 0.001
-
Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res. 1987 Mar 01; 47(5):1457-60.
Score: 0.001
-
Enhancement of methotrexate nephrotoxicity after cisplatin therapy. Cancer. 1986 Dec 15; 58(12):2617-21.
Score: 0.001